βsecretase inhibitor i

β-Secretase Inhibitor I is a highly potent inhibitor of the β-secretase enzyme. This compound exhibits exceptional inhibitory activity while also demonstrating a significant reduction in cardiovascular and liver toxicity.

AHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.

Ubiquitin Isopeptidase Inhibitor I, G5 is a caspase-independent inducer of cell necrosis that induces cell death via the death receptor pathway (IC50 of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively).

PRL-3 Inhibitor I (BR-1) is a phosphatase of regenerating liver 3 (PRL-3) inhibitor which blocks the migration and invasion of metastatic cancer cells.

δ-secretase inhibitor 11 is an inhibitor of δ-secretase and can be used as a lead compound for translational development of AD treatment.

Glyoxalase I inhibitor 4 is a potent inhibitor of glyoxalase I (GLO1) (Ki: 10 nM).

Topoisomerase I inhibitor 8, a hexacyclic analogue of camptothecin, is also a potent inhibitor of topoisomerase I and is toxic to tumour cells.

Topoisomerase I II inhibitor 3 (compound 7) is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) that inhibits the PI3K Akt mTOR signaling pathway, subsequently inhibiting cell proliferation, invasion, and migration, and inducing apoptosis. This compound has research value in liver cancer.

Topoisomerase I inhibitor 5 is an efficient topoisomerase I inhibitor with an IC50 value, effectively disrupting DNA and inhibiting topoisomerase I activity. It induces apoptosis in MCF-7 cells and arrests the cell cycle at the G1 phase, displaying potency in reversing P-gp-mediated resistance to Adriamycin [1].

Topoisomerase I inhibitor 7 (Compound 8) is a potent Topoisomerase I inhibitor that significantly reduces tumor growth by up to 79% and extends the lifespan of mice bearing P388 lymphoma transplants by 153%.

Topoisomerase I Inhibitor 9 (compound 3d), a specific inhibitor of leishmanial topoisomerase IB, exhibits antileishmanial activity, demonstrating an IC50 value of 34.81μM against L. donovani promastigotes [1].

Human PD-L1 inhibitor I is a peptide ligand that specifically inhibits the interaction between human PD-L1 and human PD-1, exhibiting a KD value of 3.39 μM, indicating its binding affinity. The presence of Human PD-L1 inhibitor I disrupts their binding, thereby attenuating their respective functions.

BACE-IN-1 is amyloid precursor protein beta-secretase inhibitor

MMP inhibitor I is a peptide inhibitor of matrix metalloproteinase-1 (MMP-1), MMP-2, and MMP-3 (IC50s = 1.3, 30, and 150 μM, respectively). It is selective for MMP-1, MMP-2, and MMP-3 over the proteases thermolysin, urease, trypsin, α-chymotrypsin, plasmin, and elastase at concentrations up to 4 mM.

Topoisomerase I inhibitor 4 (compound 7a) is a potent inhibitor of topoisomerase I activity, effectively inhibiting the proliferation of various cancer cell lines, including HepG2, A549, MCF-7, and HeLa, with IC50 values of 1.20 μM, 2.09 μM, 1.56 μM, and 1.92 μM, respectively. Thus, Topoisomerase I inhibitor 4 holds promise for cancer research applications [1].

Glyoxalase I inhibitor 1 is a potent inhibitor of glyoxalase I (GLO1) (IC50: 26 nM).

Topoisomerase I (Compound ZML-14) inhibitor 3 induces HepG2 cell apoptosis and arrests cell cycle at G2 M phase. Topoisomerase I inhibitor 3 is an inhibitor of topoisomerase I that interact with topoisomerase I-DNA complex [1].

Glyoxalase I inhibitor 2 (compound 26) is a potent inhibitor of glyoxalase I (GLO1) with an IC50 of 0.5 μM, and has potential applications in depression and anxiety studies.

Flaviviruses-Inhibitor-I is several viruses belonging to the family of Flaviviridae inhibitor.

β-Secretase Inhibitor II is a tripeptide aldehyde inhibitor of β-Secretase with an inhibitory potency of IC50 = 700 nM against total Aβ and IC50 = 2.5 μM against Aβ[1-42]. This compound, with a simple structure, is particularly useful in Alzheimer's disease research.

MMP-8 Inhibitor I is a selective inhibitor of the neutrophil collagenase matrix metalloproteinase-8 (MMP-8) with an IC50 value of 4 nM.

MMP-9 MMP-13 Inhibitor I is a dual inhibitor of MMP-9 and MMP-13 with IC50 of 0.9 nM for both enzymes. It is over 20 times more selective for MMP-9 MMP-13 than for other MMPs.

Topoisomerase I/II inhibitor 4 is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) with inhibitory effects on cell proliferation, invasion and migration, and induction of apoptosis, and can be used to study hepatocellular carcinoma.

Topoisomerase I inhibitor 2 (ZML-8) is a highly selective DNA topoisomerase I (Top1) inhibitor that impedes Top1 activity, causing DNA damage. It arrests the cell cycle at the G2 M phase and induces apoptosis, exhibiting anti-tumor effects [1].

β-Secretase Inhibitor IV is a potent, cell-active inhibitor of BACE-1, with IC50 values of 15.6 nM and 16.3 nM at BACE-1 concentrations of 2 nM and 100 pM, respectively.

IRAK-1-4 Inhibitor I is a dual inhibitor targeting IRAK1 and IRAK4.

MMP-2 MMP-9-IN-1 is a potent, highly selective, and orally bioavailable inhibitor of type IV collagenases [MMP-9 and MMP-2], exhibiting IC50 values of 0.24 μM for MMP-9 and 0.31 μM for MMP-2, which can be used to study cancer.

Glyoxalase I inhibitor 6 (Compound 9j) is an inhibitor of glyoxalase I (Glo-I) with an IC50 of 1.13 μM, exhibiting potential as a low-toxicity anticancer agent [1].

Topoisomerase I II inhibitor 2 (compound 1a) is a DNA topoisomerase I II dual inhibitor that significantly reduces xenograft tumor growth in a mouse model, indicating its potential use in treating liver cancer. It is a potent topoisomerase inhibitor with IC50 values of 6.83 μM and 9.82 μM for LM9 cells and Huh7 cells [1].

Glyoxalase I inhibitor 7 (Compound 6) is a potent glyoxalase I (Glo-I) inhibitor with an IC50 of 3.65 μM, exhibiting potential as an anticancer agent [1].

Topoisomerase I inhibitor 6 (Compound 3) is a potent Topoisomerase I inhibitor that traps the DNA-Top1 cleavage complex and exhibits low cytotoxicity in non-cancerous cell lines, making it valuable for research.

β-Secretase Inhibitor III is a highly selective inhibitor of BACE1 with a Ki value of 0.13 nM.

Topoisomerase I inhibitor 11 effectively inhibits Topoisomerase I and has the capability to bind to BTK [1].

MMP-9 inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC50s = 5, 1,050, and 113 nM, respectively). It also decreases the activity of TNF-α converting enzyme (TACE) in a dose-dependent manner (IC50 = 0.54 μM). MMP-9 inhibitor I decreases TNF-α secretion stimulated by LPS in BV-2 microglial cells when used at concentrations of 50 and 100 μM.

Glyoxalase I inhibitor 5 (Compound 9h) is a potent glyoxalase I (Glo-I) inhibitor with an IC50 of 1.28 μM, showing potential as an anticancer agent [1].

Glyoxalase I Inhibitor 3 (compound 22g), a potent inhibitor of glyoxalase I (GLO1), demonstrates an IC50 of 0.011 μM, indicating significant efficacy. This compound shows promise for research into depression and anxiety [1].

Glyoxalase I inhibitor (free base), a candidate for anticancer agents, is a potent Glyoxalase I (GLO1) inhibitor.

Glyoxalase I inhibitor, a candidate for anticancer agents, is a potent Glyoxalase I (GLO1) inhibitor.

Compound 13, a topoisomerase I inhibitor 10, selectively inhibits leishmanial topoisomerase IB and exhibits antileishmanial activity. Specifically, it demonstrates efficacy against L. donovani promastigotes with an IC50 value of 27.91 μM [1].

PKCβII Peptide Inhibitor I, a specific PKCβII inhibitor, exhibits cardioprotective properties in a rat cardiac ischemia/reperfusion injury model and mitigates vascular endothelial dysfunction [1].